Clinical Research Directory

Inclusion Criteria: * Man or woman over the age of 18 years. * Willing and able to sign the informed consent. * A clinical diagnosis of chronic HF that is considered by patient's cardiologist/physician or an experienced clinician to be stable over the one-month period prior to randomization. * Receiving oral furosemide (or equivalent doses of torsemide or bumetanide) for about 30 days prior to randomization. * No anticipated changes in HF medications during the study period. * Premenopausal women of child-bearing potential have a negative pregnancy test prior to beginning of the study and agree to use effective contraceptive methods during the study period Exclusion Criteria: * Requirement for a diuretic other than furosemide, bumetanide or torsemide except for spironolactone, eplerenone, finerenone, or SGLT2 inhibitors, at randomization and during the study. * Myocardial infarction, stroke, transient ischemic attack, acute kidney injury or acute HF requiring admission to hospital within the last 30 days prior to randomization. * Severe / symptomatic lung disease or respiratory symptoms distinct from HF. * Urinary incontinence or inability to empty bladder. * Uncontrolled diabetes mellitus or uncontrolled hypertension. * Estimated GFR \< 30 ml/min/1.72m2. * History of flash pulmonary edema or amyloid cardiomyopathy. * Female patients who are breastfeeding.